Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen LUMAKRAS / LUMYKRAS (sotorasib by Year
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Rest of World (ROW) product sales ($M) ($M)
Amgen LUMAKRAS / LUMYKRAS (sotorasib: $152M in FY2025, up 11.8% from a year earlier.
Where the FY2025 figure comes from
“|| LUMYKRAS — ROW | 152 | 12 | % | 136 | 64 | % | 83”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 152 | +11.8% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 136 | +63.9% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 83 | +31.7% | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 63 | +687.5% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 8 | – | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
Cite this data
StockData. (2026). Amgen LUMAKRAS / LUMYKRAS (sotorasib ($M), annual FY2021–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-lumakras-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.